Warfvinges väg 35
About BioArctic ABBioArctic AB is a Swedish privately held research-based biopharmaceutical company founded in 2003. The company’s mission is to provide new and effective treatments for patients with disorders in the central nervous system. Its proprietary technology and dedicated personnel have made it possible to develop new immunotherapeutic approaches to neurodegenerative diseases. We focus on therapy areas with a large medical need such as Alzheimer’s disease, Parkinson’s disease and spinal cord injury.
CEO: Gunilla Osswald
CSO: Christer Möller
CMO: Hans Basun
Please click here for BioArctic job opportunities.
Please click here for clinical trial information.
39 articles with BioArctic AB
BioArctic's Partner Eisai Initiates the Confirmatory Phase 3 Study of BAN2401 in Early Alzheimer's Disease
BioArctic AB announced that its partner Eisai has initiated the global Phase 3 confirmatory study of BAN2401 in patients with early Alzheimer´s disease.
BioArctic AB comments on the decision by Nasdaq Stockholm to halt trading in BioArctic due to large movements in the share price.
BioArctic AB announced that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is responsible for the clinical development of ABBV-0805.
BioArctic: Eisai Announces Timelines for the Single Confirmatory Phase 3 Study With BAN2401 in Warly Alzheimer's Disease
BioArctic AB informs that Eisai today announced the timelines for the single confirmatory Phase 3 study with BAN2401 in early Alzheimer´s disease patients i.e. mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease.
BioArctic's partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer's disease. AbbVie in-licensed the Parkinson portfolio
BioArctic's Product Candidate SC0806 for Treatment of Patients With Complete Spinal Cord Injury is now in Phase 2
BioArctic AB announced that the first patient in the second panel of the Phase 1/2 study now has been treated with SC0806.
BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that AbbVie has received approval from the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for ABBV-0805.
BioArctic AB to publish the company’s Full Year Report for the period January – December 2018 on Thursday, February 14, 2019 at 08:00 a.m. CET.
BioArctic Announces That Eisai Will Initiate Phase 3 Confirmatory Study With BAN2401 in Early Alzheimer's Disease
BioArctic AB announced that Eisai stated at their Q3 FY2018 Financial Results Meeting on February 4, 2019 that a single Phase 3 confirmatory study of BAN2401 in early Alzheimer´s disease patients is under preparation and planned to be initiated within Eisai's FY2018 i.e. the first quarter 2019.
BioArctic AB announced today that Gunilla Andersson assumes the new position as Senior Director HR in the management team as of January 1, 2019.
BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance
BioArctic AB announced today that BioArctic and its partner AbbVie (NYSE: ABBV) have received U.S. Federal Trade Commission (FTC) clearance to license BioArctic's alpha-synuclein antibody portfolio for Parkinson's disease and other potential indications to AbbVie.
BioArctic AB will present at Jefferies 2018 London Healthcare Conference on November 15, at 4.40 p.m. local time (GMT).
BioArctic is awarded grant from EU’s Horizon 2020 for participation in research consortium for better diagnostic tools and biomarkers for Parkinson’s
BioArctic AB has been awarded a grant from EU’s research and innovation program Horizon 2020.
BioArctic reports strong BAN2401 Phase 2b results for Alzheimer patients. AbbVie exercises its option to a license for Parkinson’s projects
BioArctic reports strong BAN2401 Phase 2b results for Alzheimer patients.
According to the resolution of the Annual General Meeting in BioArctic AB (publ) on May 15, 2018 the members of the Nomination Committee for the 2019 Annual General Meeting shall be appointed through a procedure where the three largest shareholders in terms of voting power according to Euroclear’s transcription of the share register as of September 30, 2018 are contacted by the Chairman of the Board and asked to appoint one representative each to the Nomination Committee.
BioArctic's Partner AbbVie Exercises its Option to License the Alpha-synuclein Antibody Portfolio for Parkinson's Disease
BioArctic AB announced today that the company has received a Notice of Option Exercise under the Research, Development, Option and License Agreement dated as of September 15, 2016 between AbbVie (NYSE: ABBV) and BioArctic.
Invitation to presentation of BioArctic’s Interim Report for the period January – September 2018 on November 8, 2018
BioArctic AB to publish the company’s Interim Report for the period January – September 2018 on Thursday, November 8, 2018 at 08:00 a.m. CET.
BioArctic Announces Additional BAN2401 Phase 2b Study Results in Early Alzheimer's Disease Presented by Eisai at the 2018 CTAD Conference
BAN2401 is a selective anti-amyloid beta (Aβ) protofibril antibody.
BioArctic is Granted a Concept Patent in Europe for the Company's Strategy for Disease-modifying Treatment of Parkinson's Disease
BioArctic AB announced today that the European Patent Office (EPO) has issued a decision to grant the company's patent application in Europe, EP09738534.8, for its Parkinson's disease concept patent. The decision states that the European patent, EP 2 282 758 B1, will enter into force on November 21, 2018.